metabolism Summary Salazosulfapyridine(Sulfasalazine, SASP) labelled with 14C in the carboxyl group and with 3H in the benzenesulfonyl ring was administered intravenously or orally to male and female beagle dogs with and without bile fistulas in order to study the pharmacokinetics. After in travenous administration a plasma elimination half life (t1/2p) for SASP was calculated to 14 min. The volume of distribution (Vd.0 was found to be 0.471/kg and the total clearance was about 35m1/min x kg. After oral administration of 50, 250 or 500mg/kg the time for max imal plasma concentration of SASP was 1 3 hours and the maximal concentration was 2.81±1.42pM after a dose of 50mg/kg and 15.08±3.04pM after 500mg/kg body weight. The bioavailability varied between 5.4-30% which is within the same range as reported from studies in man. The renal clearance was between 0.1-0.2m1/minxkg. Metabolites of SASP were separated by HPLC and identified by mass spectrometry. 5 aminosalicylic acid (5ASA), sulfapyridine (SP) and its glucuronide were found in plasma and urine. 5ASA, N-acetylated 5ASA (Ac5ASA), SP and unmetabolized SASP were found in faeces.
The cumulative biliary excretion of SASP after i.v. administration was as a mean 95% of the administered dose. Similar figures were obtained for the 14C and 3H radioactivity. Thus a quantitative excretion of the unchanged drug was found in the bile during 24 hours after administration and >90% was recovered during the first 2hours. No metabolites were found in the bile. After oral administration of SASP 18% of the administered dose was recovered as the unchanged drug in bile, 17% as 14C and 19% as 3H radioactivity within 48 hours. As after intravenous administration no metabolites were found in bile after the oral administra tion.
The total recovery of excreted radioactivity after i.v. and oral administration was 69-96 %. The tritium radioactivity representing the SP metabolites was mainly found in urine, while carbon-14 representing SASP and 5ASA metabolites was preferentially excreted in fae ces. This is in accordance with the higher absorption of SP and its metabolites, compared to 5ASA which is poorly absorbed and thus mainly eliminated via faeces together with a small amount of unchanged SASP.
INTRODUCTION
In the preceding papers the pharmacokinetics of SASP in the rat has been described.
As a complement to these studies and since toxicological studies have been performed not only in rats but also in dogs, this paper will deal with the pharmacokinetics of SASP in the dog after a single intravenous or oral administration. The present study was de signed to facilitate comparison with data obtained from rats. The elimination of SASP and its metabolites were followed in plasma, urine, faeces and bile and kinetic parame ters were calculated. To our knowledge no such data are available in the literature.
MATERIALS AND METHODS

Materials
C14CJSASP and C3HISASP were synthesized according to a synthetic route as previously described'). The specific activity of C14CiSASP was 76MBq/mmol (2.05mCi/mmol) and the specific activity of C3HiSASP was 1.09GBq/mmol (29.5mCi/mmol). into the bile duct and secured. The pancreatic duct was also ligated. The distal part of the bile duct was ligated into the intestine and the suture used to guide another catheter into the intestine and also used as fixation. The bile duct was cut as mentioned earlier.
The catheter was cut to a desired length. Three side holes were cut above the tip. The catheter was then guided through the hole in the bile duct so the 3 holes in the catheter were placed in the intestinal lumen and secured. The proximal and distal catheters were connected with a suitable extension to avoid leakage into the abdominal cavity during the preparation and to control function. A cut was made in the abdominal muscle and skin in a place suitable in relation to the bile duct and convenient and not readily accessible for the dog. The base plate of a specially constructed bile fistula was guided to the out side and fixed with sutures in the abdominal muscle. The edges of the abdominal muscle and the skin were fitted in to milled out slits in the fistula and closely sutured. The catheters were disconnected, guided through tightly fitting holes in a silicon membrane in the center of the fistula and reconnected. The catheter leading to the intestine was labelled. A cover was screwed on. The peritoneum and the abdominal muscle were su tured with silk, the skin with stainless steel suture. After bile fistula operation the animals were allowed to recover during at least one week before administration.
Sample collection
After intravenous administration blood was collected at the following times : 0, 5, 10, 20, 30, 40, 60 and 90 minutes and after : 2, 3, 4, 6 and 8 hours. Urine and faeces were collected during the following time intervals at : 0-24, 24-48, 48.72, 72-96 and 96-120 hours. After oral administration blood was collected at the following times : 0, 0. 5(64 : 36, v : v) . The column was kept at 37'C and the flow rate was set to lml/min.
Faeces samples were homogenized in methanol, 1. 5 times its weight and were centrifu gated at 1000g for 10 min. An aliquote of 100µl supernatant was diluted with 100µl water and 20µl of the mixture was injected into the chromatography system.
The detection limit of SASP in dog plasma was 1.4pmole/l, in dog urine 4.lµmole/l, in dog faeces 3. 6µmole/l and in dog bile 7. 9pmole/l. The coefficient of variation was<4.5 % at 100pmole/l and < 7 % at 1.3-5µmole (n 10). The accuracy was 101107% and the relative recovery 99-101% (n =6) at 100pmole/l.
Analysis of metabolites
To the plasma, urine or bile samples (l00µ 1) were added 10µl 1M acetate buffer and 5µl p-glucuronidase/arylsulfatase and the mixture was incubated at 371C for 3 hours. The faeces samples were homogenized in methanol, 1.5 X faeces weight. An aliquot of 150µl of the supernatant obtained after centrifugation was evaporated and redissolved in 150µl
of water and 10µl of p-glucuronidase/arylsulfatase. The faeces samples were further trea ted as the other matrices. The incubations were stopped by addition of 400µl of methanol and the samples were allowed to stand for 15 minutes. The samples were centrifugated and 20µl of the supernatant was injected into a high performance liquid chromatography system with a reversed phase (Nucleosil C18, 7µm) column and precolumn (Perisorb RP -18 , 30--40µm).
The mobile phase was a mixture of water containing 5.3M hexanesul phonic acid and 10mM phosphoric acid, methanol and triethylamine (920: 180:0.3). The flow rate was set to lml/min.
A UV-detector (254nm), a fluorescence detector (315/470 nm) and an electrochemical(+0.6V) detector were connected in series for determination of SP, SPOH (UV) and Ac5ASA, AcSP (fluorescence) and 5ASA (electrochemical). Aliqoutes of 50pl were injected directly via a sample injection loop into the mass spectro meter. The flow rate of the mobile stream, MeOH/0. 5M NH Ac (30 : 70), was set to 1 . 2 ml/min. Argon (0.5mtorr) was used as collision gas to obtain daughter ion mass spec tra. Vaporizer and block temperature as well as repeller potential and collision energy were optimized for each substance.
RESULTS
Plasma kinetics
The plasma elimination of SASP, 14C and 3H during the first hour after intravenous administration is presented in Fig. 1 . The plasma concentrations of SASP were only measurable during the first 40 minutes after administration. The concentration of radioac tivity showed an elimination rate parallel with that of SASP. The initial plasma half-life (t1/2a) including the distribution phase was 4 min and the plasma half-life elimination t1/2p was 14±3 min (mean±SEM). The apparent volume of distribution (Vdss) was 0.47 ±0.061/kg and the plasma clearance (CLtot) was 34 .80±1.79m1/min x kg (mean±SEM). The values calculated for 14C and 3H were similar (Table  I ) . Two to three hours after the i.v. administration the radioactivity rose and peak concentrations were reached after 6
hours reflecting the appearance of splitting products of SASP (Fig. 2 ) . The tritium con centration representing SP and its metabolites was higher than the carbon-14 level repre senting the 5ASA metabolites.
In the bile fistula operated dogs the plasma half-life(t1/2p) of SASP after i.v. admin 250mg/kg p.o., were 6.31±0.48µM and 11.48+_2.26µM respectively. There was a pro nounced interindividual variation in the plasma concentrations of SASP. These data in dicate that the major absorption site of SASP was in the small intestine. After oral administration to bile fistula operated dogs Tmax varied between 4-10 hours with a Cmax in the range of 86-562µM SASP. The bioavailability in non operated male dogs were 5.4, 30.1 and 15.6% at the doses of 50, 250 and 500mg/kg respectively and 19.9% for female dogs receiving 250mg/kg. The plasma half-life (t1/2p) of SASP was 4.13±0.44 hours, (250mg/kg, p.o. male) and 5.43±2.2 hours, (500mg/kg p.o.) The data obtained for the 50mg p.o. dose were too few for calculation of the elimination half-life.
The radioactivity persisted for much longer time in plasma due to the formation of metabolites by reductive cleavage of SASP. 3H and 14C corresponding to sulfapyridine and SASA respectively with their metabolites gave maximal plasma concentrations varying between 6 -24 hours depending on the dose (Fig. 4 ) , with higher dose the Cmax was shifted to a later time.
Biliary excretion
The cumulative biliary excretion of SASP after intravenous administration was 98%(90 -106%) and 92% (87-97%) in female and male dogs respectively . The major part was eliminated during the first 2 hours after administration (Fig. 5 ) . Measured as radioac tivity the biliary excretion in female and male dogs were for 14C 89% and 103% and for 3H 89% and 101% respectively . It is evident that SASP is eliminated unchanged via bili ary excretion and thus no metabolites were found in bile after i.v. administration. The mean cumulative biliary excretion of SASP after oral administration was almost completed 48 hours after administration and amounted to 16% (14-19%) for female and 19% (17-22%) for male dogs (Fig. 6 ) . The corresponding figures for 14C was 17% (12 21%) and for 3H 19% (9-28%) for both female and male dogs . As after intravenous administration no metabolites were found in bile.
Urinary and fecal excretion
The intravenous as well as the oral doses were excreted quantitatively within 48 hours in urine and faeces. The recoveries from the dogs given [3H, 14CISASP 250 or 500mg/kg body weight orally were approximately 90% of the given dose while the recoveries from the dogs given [14C, 3HISASP 50mg/kg body weight orally and after the intravenous dose were slightly lower (Figs. 7-10, Table III ). The amount of SASP excreted un changed after oral administration ranged as a mean between 0.1627.39% of the dose and the main part was found in faeces (Table III) . No unchanged SASP was recovered (Table N) . The sum of SP metabolites and SASP corresponded well to that of the recovered 3H in urine and faeces, while the recovery of 14C was much higher compared to the sum of SASP and Ac5ASA (Table V) . This is explained by the fact that 5ASA was not determined in urine and faeces due to methodological problems. 5ASA is however a major metabolite in urine and faeces from dogs as judged by the radioactivity profiles in Fig. 11 and 12.
Metabolism
Metabolic profiles were obtained from urine and faeces samples, containing the highest radioactivity, collected during 8-24 hours after administration and plasma samples collected after 14 hours, from male and female dogs given SASP 250mg/kg body weight p.o. Faeces from a female dog contained 5ASA, SP and SASP (Fig. 11 a ) . The meta bolite profile of faeces from a male dog contained in addition to 5ASA, SP and SASP also Ac5ASA (Fig. llb) . The concentration of Ac5ASA in faeces from the female dog was too low to give any response in the radioactivity flow detector but a small peak was seen in the UV chromatogram. The urine from male and female dogs also showed similar profiles and contained SP and SPglucuronide together with 5ASA (Fig. 12) . Plasma sam pies contained 5ASA, SPglucuronide and SP (Fig. 13) 200 and 266. The latter formed from m/z 442 after the loss of 176 which corresponds to the glucuronide moiety (Fig. 14) . The metabolite pathways of SASP in the dog are illus trated in Fig. 15 . rat and the dog. The Vdss calculated from single dose administration was similar for rats, dogs and man 0. 10.71/kg, which is close to the blood volume indicating a low tissue distribution. The total clearance was 34.8 in the dog and in the rat 17.9m1/min x kg, while the clearance in man was 100 fold lower. Thus the dominating difference be tween man and the animals studied was a lower clearance in man. After oral admin istration the time for maximal plasma concentration was 1-3 hours in both dogs and rats, while it was longer in man (6 hours).
After intravenous administration intact SASP was rapidly excreted in bile. In the non operated animals the SASP delivered to the intestine viabile was reduced by azo reductase s and the metabolites were absorbed. The tritium labelled SP metabolites were absorbed to a higher extent than the carbon-14 labelled 5ASA and Ac5ASA as shown in Fig. 2 .
